All News
The Red Eye in the Rheumatology Patient
Professor Rosenbaum is well known for his expertise in rheumatic eye disease and he gave a great summary of how to approach your patient having a red eye.
Key Takeaways from ACR Review Course
The ACR Review Course was superb once again from top to bottom, from Blue Fingers to Practical Treatment of RA. Every year I wonder if I should skip it, but each year I go. And I have never regretted it. Here are my take-home messages and “pearls” from the ACR Review Course.
Read Article
Abbvie's Robust ACR Presentations
AbbVie announced that data from 38 abstracts of HUMIRA® (adalimumab) and the company's portfolio of investigational immunology medicines will be presented at the 2017 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) Annual Meeting, November 3-8, in S
Read Article
Uveitis Events Reduced with Select TNF Inhibitors
Uveitis may occur in up to 40% of spondyloarthritis patients. Metanalyses have shown that treatment with tumour necrosis factor-α inhibitor may reduce the rates of anterior uveitis. A multicenter study from Sweden and Norway has confirmed that amongst TNFi, adalimumab and infliximab offer better protection against AU than etanercept.
Read Article
Pediatric Consensus on Comorbidity Assessments
Comorbidity is a serious consequence or confounder in patients with inflammatory diseases. This has been well described in both psoriatic and rheumatoid disease.
Read Article
NEJM: Adalimumab and MTX Effective in JIA Uveitis
The NEJM has published the results of a randomized, placebo-controlled trial showing adalimumab and methotrexate is effective in reducing ocular flares in juvenile idiopathic arthritis with uveitis.
Read Article
Inconsistent ESR & CRP in Spondylitis Patients
Patients with active axial spondyloarthritis (axSpA) can lack evidence of inflammation on magnetic resonance imaging (MRI) but may develop evidence of inflammation over time.
Read Article
The RheumNow Week in Review – 10 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com. Sign up at RheumNow.com to received daily or weekly news, blogs and tweets on all things rheumatology
Read Article
TNF Inhibitor Therapy and the Risk of Anterior Uveitis Recurrence
The TNF inhibitor drug development trials have indirectly taught us that monoclonal antibody based TNFi was capable of retarding the recurrence of anterior uveitis (AU) in patients with ankylosing spondylitis (AS).
Read Article
RheumNow Week in Review – 14 October 2015
Dr Jack Cush reviews highlights from the news and journal articles appearing this week on RheumNow.com:
Read Article
My Take on New Ocular Screening Guidelines for Plaquenil
A recent article published by the American Academy of Ophthalmology presented new recommendations for screening of patients being managed with hydroxychloroquine that changed the previous monitoring paradigm. More importantly, it has repositioned hydroxychloroquine from one of the safest medications that rheumatologists use to a drug that can have potentially significant ocular morbidity (if used in doses greater than 5 mg per kilogram and or for prolonged periods of time).
Adalimumab Lowers Risk of Uveitis Flares in Visual I Study
Rheumatologists may encounter patients with intermediate, posterior and pan-uveitis as part of certain rheumatic diseases such as Behcet’s, but more frequently may be called on to co-manage these patients with steroid sparing agents.
Read Article
RheumNow Week in Review – 26 August 2016
Dr. Jack Cush reviews news and journal reports from the past week on RheumNow.com.
Read Article
Adalimumab Controls Non-Infectious Uveitis in VISUAL II Study
It has long been observed that patients receiving monoclonal antibody based anti-TNF (TNFi) therapies for spondylitis or psoriatic disease have less inflammatory eye complications, such as uveitis. These agents have become common interventions based on these observational results.
Read Article
Rheumatologists May be Unaware of New Hydroxychloroquine Retinopathy Monitoring Guidelines
Rheumatologists are well-acquainted with the rules for hydroxychloroquine (HCQ) retinopathy screening: A) annual visits to the ophthalmologist and B) maintain HCQ doses at less than 6.5 mg/kg to avoid retinopathy.
Read Article
RheumNow Week in Review – 15 July 2016
Dr. Jack Cush reviews highlights from this week's rheumatology news on RheumNow.com.
Read Article
Adalimumab Approved for Uveitis
Autoimmune ophthalmic disease is a frequent challenge to rheumatologists from both a diagnostic and therapeutic perspective. Approved therapies are limited and have only been infrequently or comfortably utilized by rheumatologists and autoimmune ophthalmologists.
Read Article
New EULAR Guidelines on Behçet's
At the EULAR 2016 meeting, new EULAR recommendations for the management of Behçet's disease (BD) were presented.
Read Article
Posterior Reversible Encephalopathy in Lupus
Posterior reversible encephalopathy syndrome (PRES) is a rare neurological disorder with many associations or causative factors that rarely includes autoimmune disorders and lupus.
Read Article
GCA: Uptick in Severe Infections in First Year
Patients with giant cell arteritis (GCA) had a higher rate of severe infections compared with the general population, a French study found.
Read Article